Treatment of T-cell large granular lymphocyte leukemia with cyclosporine A: experience in a Chinese single institution.

Abstract

T-cell large granular lymphocyte leukemia (T-LGLL) is a rare chronic lymphoproliferative disorder. Available reported data on the treatment regimens of this disease are variable and limited due to low number of patients. We analyzed the efficiency of cyclosporine A (CsA) in the treatment of 28 patients with T-LGLL. The overall response rate (ORR) was 82.1% with hematologic complete remission (HCR) rate of 57.1%. The median time to response (TTR) was 1.8 months and treatment duration with CsA-based regimens was 34.5 months. CsA shows low and manageable toxicity during treatment. Twenty-one patients survived with a median follow-up time of 42.0 months. Our results indicate that CsA is efficacious and safe in the treatment of T-LGLL.

• Authors: Xin Zhao, Kang Zhou, Liping Jing, Li Zhang, Guangxin Peng, Yang Li, Lei Ye, Jianping Li, Huihui Fan, Yuan Li, Fengkui Zhang
• Journal: Leukemia research (Leuk Res) Vol. 37 Issue 5 Pg. 547-51 (May 2013) ISSN: 1873-5835 [Electronic] England
• PMID: 23395383 (Publication Type: Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: Copyright © 2013 Elsevier Ltd. All rights reserved.

Chemical References

• Immunosuppressive Agents
• Cyclosporine

Topics

• Adult
• Aged
• China
• Cyclosporine (administration & dosage)
• Disease-Free Survival
• Female
• Follow-Up Studies
• Humans
• Immunosuppressive Agents (administration & dosage)
• Leukemia, Large Granular Lymphocytic (drug therapy, mortality)
• Male
• Middle Aged
• Retrospective Studies